Veeva Systems remains a beaten-down healthcare SaaS leader that the market is pricing as if the business were broken, a view strongly disputed here. It ranks among the best risk/reward setups found in a search of beaten-down SaaS names. x.com 

Veeva Systems will probably be one of the first companies to deliver real AI benefits to its clients and customers. Its latest report was excellent, with growth hitting solid double digits in everything that matters, and the stock rose 6-7% after hours. The weekly chart shows possible resistance around $263. x.com 

Veeva is one of the most investible SaaS names thanks to the industry it serves and its GAAP margins. Its legal battle with IQVIA appears to be over, and the two now partner in many areas, with IQVIA joining Veeva's CRO clinical data partner program. @JaredSleeper notes Veeva's 29% GAAP operating margin and $3.3B of ARR growing 16% a year. x.com 

Software's relative strength and sound finances make institutional rotation from semis plausible. It could lead while semis consolidate, despite slow growth at some firms; the market rewards cash flow, healthy balance sheets and manageable debt. Salesforce, ServiceNow, Palantir, Shopify and Workday hold up; SAP's cloud and AI shift, Instacart's massive 10-month base, Veeva's massive five-year base and Atlassian's Stage 2 strength add to the case. Semis may still rally; the view can change. x.com  … Show more

Veeva Systems looks attractive based on a deep-dive analysis by @hollertotide, described as fascinating and as alpha. x.com 

Adobe, Salesforce and ServiceNow still generate massive cash flow, push deeper into AI and sit at the center of enterprise operations. Three of the biggest SaaS names remain beaten up in 2026; their valuations have been crushed, but the long-term opportunity may not have been. The market has swung way too far against them. x.com 

Salesforce's strong free cash flow and healthy balance sheet support its setup as enterprise AI adoption, Agentforce and AI-driven workflow automation advance. Its earnings gap on four times average volume has been followed by a tightening formation. x.com  x.com 

Schrodinger deserves at least a 50% higher valuation than Salesforce, yet both trade near 3.9x EV/sales. The better test of AI is how much upside optionality an industry gains, not whether a company wins or loses: Salesforce's AI upside is capped because demand is saturated and it must fight to capture value across the stack. Biotech research is far more uncapped, since better modeling could turn a pipeline of 3 drug candidates into 30 with higher approval odds. x.com 

Salesforce's $25 billion accelerated buyback leans on debt in a way that risks leveraging its future, as happened at Fiserv. Fiserv cut its share count 21.5% with debt-funded buybacks averaging $167 a share, and now trades under $60 as growth fell. Salesforce can afford this round with $14 billion of free cash flow, but growth is slowing to single digits, AI isn't yet transforming its ecosystem, and its goodwill-heavy book limits deals. The risk is that multiples compress and it doubles down. … Show more

Salesforce is no longer cheap enough given how much wallet share core CRM is losing. Organic growth only matches nominal GDP despite a massive increase in agentic spending, and large enterprises increasingly see Salesforce as a data pipe for their own custom agents, an ex-growth business that deserves a low multiple. The Informatica acquisition doubles down on that weak model. Salesforce was too cheap at 12x non-GAAP earnings, but near high-teens it is fair, and terminal risks have not abated. … Show more